Replies to post #86124 on Biotech Values

[genisi]

[After each report, Merck said doctors shouldn’t change treatment based on the results and urged them to wait for data from a larger trial to be completed in 2012.

This larger one is the IMPROVE-IT trial (Vytorin vs. Simvastatin) and should Zetia disappoint in ARBITER 6, outcome for Vytorin in the IMPROVE-IT trial looks shady.